Boston Scientific reports weaker results, sets job cuts

(Reuters) – Boston Scientific Corp reported weaker quarterly earnings on Tuesday as sales slipped and expenses rose, and the medical device maker announced more job cuts. The company said it expected to eliminate 900 to 1,000 jobs worldwide through 2013, bringing the total headcount reduction to 2,100 to 2,400 positions from 2011 to 2013. Boston Scientific employs 24,000 workers worldwide, according to its website. Fourth-quarter net earnings fell to $60 million, or 4 cents per share, from $107 million, or 7 cents per share, a year earlier, the company said. …

FAO urges cash-strapped governments to keep up guard against bird flu

ROME (Reuters) – Governments must not allow financial constraints caused by the current global economic crisis to stop them keeping their guard up against avian flu, the Food and Agriculture Organisation (FAO) said on Tuesday. The agency, one of three international bodies that lead the global response to bird flu, warned of a repeat of the 2006 outbreaks, when the highly pathogenic H5N1 virus killed 79 people around the world and sparked fears of a pandemic. Investment was vital to prevent a repeat of such a crisis, the FAO said. …

NFL players union funding $100 mln Harvard study on injury

BOSTON, Jan 29 (Reuters) – The union that represents U.S. professional football players has given Harvard University a $100 million grant for a study of the range of health problems, from brain damage to heart conditions, that affect current and former players. Researchers with Harvard Medical School plan to spend a decade studying hundreds of former players who are members of the National Football League Players Association, school officials said on Tuesday. The aim is to develop strategies to limit the long-term damage that players suffer from years of hits on the field. …

Lilly says generic competition hurts fourth-quarter profit, sales

(Reuters) – Eli Lilly and Co said on Tuesday that fourth-quarter profit fell as competition from generic drugs, particularly for its once top-selling schizophrenia drug Zyprexa, drove revenue lower. The U.S. drugmaker earned $827 million, or 74 cents per share, down from $858 million, or 77 cents per share, a year earlier. Excluding special items such as asset impairments and restructuring, Lilly earned 85 cents per share, beating analysts’ expectations by 7 cents per share. …

1 893 894 895 896 897 977